Everett Laboratories, Inc., a leader in the field of prenatal supplementation, today announced that it had filed a patent infringement lawsuit with a motion for a preliminary injunction in the United States District Court of New Jersey against Trigen Laboratories, Inc., a specialty niche pharmaceutical company. The lawsuit asserts, among other things, that Trigen is infringing United States Patent No. 8,183,227 covering Everett's Vitafol-One product, and seeks to prevent Trigen from making, selling, distributing and falsely branding its infringing, copycat products. Everett's lawsuit alleges that it will be irreparably harmed unless the court issues a preliminary injunction that requires Trigen immediately to withdraw its patent-infringing products from the market.
"We are fully committed to our innovation and to providing physicians and their patients with quality products for prenatal supplementation," said Lucas Sigman, Everett's Chief Executive Officer. "Our prenatal supplementation portfolio represents one of the Company's most valuable assets, and provides significant market and competitive advantages. We will not tolerate infringement of our patents, and we will do what is necessary to protect our proprietary rights."
Everett's lawsuit also alleges that Trigen's copycat products contain fish oil while Everett DHA is made from Algae oil. "We are committed to providing pregnant women with the highest-quality prenatal supplementation. That is our number one priority," said Louis Bongiovanni, Everett's Vice President of Sales.
Source: Everett Laboratories Inc.